NASDAQ:PSTI - Pluristem Therapeutics Stock Price, Price Target & More

$1.22 -0.01 (-0.81 %)
(As of 04/19/2018 01:30 PM ET)
Previous Close$1.23
Today's Range$1.20 - $1.24
52-Week Range$1.06 - $2.12
Volume27,940 shs
Average Volume316,482 shs
Market Capitalization$131.93 million
P/E Ratio-3.84
Dividend YieldN/A
Beta0.28

About Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics logoPluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8607

Debt

Debt-to-Equity RatioN/A
Current Ratio6.40%
Quick Ratio6.40%

Price-To-Earnings

Trailing P/E Ratio-3.84
Forward P/E Ratio-3.59
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.85 million
Price / Sales47.46
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book3.94

Profitability

EPS (Most Recent Fiscal Year)($0.32)
Net Income$-27,810,000.00
Net MarginsN/A
Return on Equity-95.87%
Return on Assets-77.80%

Miscellaneous

Employees183
Outstanding Shares110,870,000

How to Become a New Pot Stock Millionaire

Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) released its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). View Pluristem Therapeutics' Earnings History.

What price target have analysts set for PSTI?

3 brokerages have issued 1-year price targets for Pluristem Therapeutics' stock. Their predictions range from $3.00 to $5.00. On average, they expect Pluristem Therapeutics' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Pluristem Therapeutics.

What are Wall Street analysts saying about Pluristem Therapeutics stock?

Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
  • 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (3/27/2018)
  • 2. Maxim Group analysts commented, "Summary Pluristem announced that Austria’s regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), has cleared the study to begin enrollment in Austria. The PIII trial is currently enrolling patients in the U.S., U.K., and Germany. Pluristem is focused on showing the benefits of therapy in prolonging the time to an event. If patients can keep a limb a year longer, is the therapy viable and does it create value. We do believe the current statistical plan is well designed to show if a difference exists in the time to event analysis. What will be critical will be if US regulators will accept time to event in place of AFS for approval. It stands to reason that a treatment effect which prolongs time to event, (as is the standard on oncology) could suffice for approval in CLI (Critical Limb Ischemia). i.e. if the treated group keeps limbs longer, is the therapy approvable one and is there benefit? We must also consider changes in the regulatory landscape and what impact the adaptive pathway and 21st Century Act might have on regenerative medicine – cell therapy approval timelines." (7/10/2017)

Who are some of Pluristem Therapeutics' key competitors?

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the folowing people:
  • Mr. Zami Aberman, Chairman & Co-CEO (Age 64)
  • Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 47)
  • Mr. Erez Egozi, CFO, Treasurer & Sec. (Age 44)
  • Mr. Boaz Leshem, VP Operations & Manufacturing (Age 58)
  • Efrat Kaduri, Head of Investor & PR

Has Pluristem Therapeutics been receiving favorable news coverage?

News stories about PSTI stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pluristem Therapeutics earned a news impact score of 0.10 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.14 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $1.22.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $131.93 million and generates $2.85 million in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 183 workers across the globe.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-8607 or via email at [email protected]


MarketBeat Community Rating for Pluristem Therapeutics (PSTI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pluristem Therapeutics (NASDAQ:PSTI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Pluristem Therapeutics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 227.87%. The high price target for PSTI is $5.00 and the low price target for PSTI is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$4.1250
Price Target Upside: 227.87% upside194.12% upside148.45% upside137.07% upside

Pluristem Therapeutics (NASDAQ:PSTI) Consensus Price Target History

Price Target History for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ:PSTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Maxim GroupSet Price TargetBuy$3.00MediumView Rating Details
1/16/2018HC WainwrightSet Price TargetBuy$4.00MediumView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$5.00N/AView Rating Details
1/10/2017FBR & CoReiterated RatingBuyN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Pluristem Therapeutics (NASDAQ:PSTI) Earnings History and Estimates Chart

Earnings by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ:PSTI) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20181($0.09)($0.09)($0.09)

Pluristem Therapeutics (NASDAQ PSTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q1($0.08)($0.08)ViewN/AView Earnings Details
9/7/2017Q4 2017($0.07)($0.07)ViewN/AView Earnings Details
5/8/2017Q3 2017($0.07)($0.09)ViewN/AView Earnings Details
2/8/2017Q2 2017($0.07)($0.08)ViewN/AView Earnings Details
11/15/2016Q1 2017($0.08)($0.08)ViewN/AView Earnings Details
9/7/2016Q4 2016($0.08)ViewN/AView Earnings Details
5/9/2016Q3 2016($0.10)($0.09)ViewN/AView Earnings Details
2/8/2016Q2 2016($0.08)($0.05)$0.09 million$2.75 millionViewN/AView Earnings Details
11/9/2015Q1 2016($0.11)($0.07)$0.09 million$0.10 millionViewN/AView Earnings Details
9/10/2015Q4 2015($0.11)($0.07)$0.09 million$0.09 millionViewN/AView Earnings Details
5/6/2015Q3 2015($0.18)($0.10)$0.19 million$0.10 millionViewN/AView Earnings Details
2/5/2015Q2 2015($0.09)$0.10 millionViewN/AView Earnings Details
11/6/2014($0.13)($0.09)$0.10 million$0.10 millionViewN/AView Earnings Details
10/6/2014($0.13)($0.09)ViewN/AView Earnings Details
9/11/2014($0.15)($0.09)$0.10 million$0.09 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.14)$0.20 million$0.10 millionViewN/AView Earnings Details
2/5/2014Q2 2014($0.13)($0.11)$0.15 million$0.10 millionViewN/AView Earnings Details
11/5/2013Q1 2014($0.13)($0.08)$0.15 million$0.10 millionViewN/AView Earnings Details
9/11/2013Q4 2013($0.13)($0.12)$0.10 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.09)($0.10)$0.20 million$0.19 millionViewN/AView Earnings Details
1/31/2013Q2 2013($0.09)($0.08)ViewN/AView Earnings Details
11/6/2012Q1 2013($0.08)($0.08)ViewN/AView Earnings Details
9/10/2012Q4 2012($0.09)ViewN/AView Earnings Details
5/8/2012Q3 2012($0.09)ViewN/AView Earnings Details
2/9/2012Q2 2012($0.05)ViewN/AView Earnings Details
11/9/2011Q1 2012($0.06)($0.11)ViewN/AView Earnings Details
9/12/2011Q4 2011($0.09)ViewN/AView Earnings Details
5/11/2011Q3 2011($0.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pluristem Therapeutics (NASDAQ:PSTI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pluristem Therapeutics (NASDAQ PSTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 4.17%
Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)
Insider Trading History for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ PSTI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Mark GermainDirectorSell45,873$1.48$67,892.04525,584View SEC Filing  
3/14/2018Mark GermainDirectorSell23,818$1.50$35,727.00559,817View SEC Filing  
2/22/2016Zami AbermanCEOBuy5,000$1.33$6,650.002,118,298View SEC Filing  
2/18/2016Yaky YanayCFOBuy5,000$1.20$6,000.001,451,616View SEC Filing  
2/16/2016Yaky YanayCFOBuy15,000$0.95$14,250.001,451,616View SEC Filing  
2/15/2016Doron ShorrerDirectorBuy12,346$0.81$10,000.26View SEC Filing  
2/12/2016Yaky YanayCFOBuy5,000$0.83$4,150.001,451,616View SEC Filing  
2/11/2016Israel Ben-YoramDirectorBuy10,000$0.79$7,900.00216,056View SEC Filing  
2/11/2016Zami AbermanCEOBuy31,000$0.80$24,800.002,118,298View SEC Filing  
11/16/2015Yaky YanayCFOBuy10,000$1.52$15,200.001,301,616View SEC Filing  
11/16/2015Zami AbermanCEOBuy9,900$1.49$14,751.001,968,298View SEC Filing  
9/21/2015Israel Ben-YoramDirectorSell30,000$2.10$63,000.00206,056View SEC Filing  
9/21/2015Yaky YanayCFOBuy10,000$2.11$21,100.001,301,616View SEC Filing  
9/21/2015Zami AbermanCEOBuy25,500$2.11$53,805.001,968,298View SEC Filing  
9/16/2015Yaky YanayCFOBuy10,000$2.12$21,200.001,301,616View SEC Filing  
9/15/2015Zami AbermanCEOBuy25,000$2.11$52,750.001,968,298View SEC Filing  
11/11/2014Yaky YanayCOOBuy11,000$2.62$28,820.00View SEC Filing  
11/11/2014Zami AbermanCEOBuy13,000$2.64$34,320.00View SEC Filing  
9/22/2014Yaky YanayCOOBuy11,000$2.95$32,450.00View SEC Filing  
9/22/2014Zami AbermanCEOBuy5,000$2.92$14,600.00View SEC Filing  
9/21/2014Zami AbermanCEOBuy5,000$2.96$14,800.00View SEC Filing  
9/17/2014Israel Ben-YoramDirectorBuy5,000$2.82$14,100.00View SEC Filing  
9/16/2014Boaz Gur-LavieCFOBuy3,478$2.84$9,877.52View SEC Filing  
9/16/2014Yaky YanayCOOBuy10,000$2.85$28,500.00View SEC Filing  
9/16/2014Zami AbermanCEOBuy15,000$2.80$42,000.00View SEC Filing  
6/18/2014Mark GermainDirectorSell43,215$3.12$134,830.80View SEC Filing  
1/17/2014Israel Ben-YoramDirectorSell35,625$4.51$160,668.75314,806View SEC Filing  
1/13/2014Israel Ben-YoramDirectorSell26,453$4.29$113,483.37350,431View SEC Filing  
1/13/2014Yaky YanayCFOSell69,850$4.29$299,656.501,069,616View SEC Filing  
1/9/2014Yaky YanayCFOSell30,150$4.25$128,137.501,139,466View SEC Filing  
1/8/2014Israel Ben-YoramDirectorSell44,797$4.12$184,563.64376,884View SEC Filing  
11/11/2013Nachum RosmanDirectorSell67,244$3.27$219,887.88View SEC Filing  
9/12/2013Israel Ben-YoramDirectorSell52,000$3.07$159,640.00371,681View SEC Filing  
5/20/2013Israel Ben-YoramDirectorSell45,429$3.03$137,649.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pluristem Therapeutics (NASDAQ PSTI) News Headlines

Source:
DateHeadline
-$0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter-$0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter
www.americanbankingnews.com - April 17 at 7:08 PM
Acorda Therapeutics (ACOR) & Pluristem Therapeutics (PSTI) Financial ContrastAcorda Therapeutics (ACOR) & Pluristem Therapeutics (PSTI) Financial Contrast
www.americanbankingnews.com - April 13 at 11:51 AM
Pluristem Therapeutics (PSTI) Upgraded by ValuEngine to SellPluristem Therapeutics (PSTI) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 11:17 AM
Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristems Strategic Advisory BoardRoger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board
finance.yahoo.com - April 6 at 5:41 PM
Pluristem Therapeutics (PSTI) PT Set at $3.00 by Maxim GroupPluristem Therapeutics (PSTI) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - April 2 at 6:58 PM
CytRx (CYTR) vs. Pluristem Therapeutics (PSTI) Critical ContrastCytRx (CYTR) vs. Pluristem Therapeutics (PSTI) Critical Contrast
www.americanbankingnews.com - April 1 at 5:38 AM
 Analysts Anticipate Pluristem Therapeutics Inc. (PSTI) to Post -$0.08 EPS Analysts Anticipate Pluristem Therapeutics Inc. (PSTI) to Post -$0.08 EPS
www.americanbankingnews.com - March 31 at 7:14 PM
Pluristem Therapeutics (PSTI) Receives Buy Rating from HC WainwrightPluristem Therapeutics (PSTI) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM
HC Wainwright Analysts Give Pluristem Therapeutics (PSTI) a $4.00 Price TargetHC Wainwright Analysts Give Pluristem Therapeutics (PSTI) a $4.00 Price Target
www.americanbankingnews.com - March 28 at 2:06 PM
Pluristem Therapeutics (PSTI) Downgraded to Hold at Zacks Investment ResearchPluristem Therapeutics (PSTI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:01 AM
Pluristem Therapeutics (PSTI) Upgraded to "Buy" by Zacks Investment ResearchPluristem Therapeutics (PSTI) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 24 at 2:26 PM
Pluristem Therapeutics (PSTI) Lowered to Hold at Zacks Investment ResearchPluristem Therapeutics (PSTI) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:13 AM
Pluristem Therapeutics Inc. (PSTI) Director Sells $67,892.04 in StockPluristem Therapeutics Inc. (PSTI) Director Sells $67,892.04 in Stock
www.americanbankingnews.com - March 19 at 8:28 PM
Pluristem Therapeutics Inc. (PSTI) Director Mark Germain Sells 23,818 SharesPluristem Therapeutics Inc. (PSTI) Director Mark Germain Sells 23,818 Shares
www.americanbankingnews.com - March 15 at 8:28 PM
Pluristem Therapeutics (PSTI) Upgraded by Zacks Investment Research to "Buy"Pluristem Therapeutics (PSTI) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 15 at 10:02 AM
Pluristem Therapeutics Inc. (PSTI) Expected to Announce Earnings of -$0.08 Per SharePluristem Therapeutics Inc. (PSTI) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - March 14 at 5:24 PM
Pluristem (PSTI) Says PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in ... - StreetInsider.comPluristem (PSTI) Says PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in ... - StreetInsider.com
www.streetinsider.com - February 27 at 8:19 AM
Pluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in MedicinePluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine
finance.yahoo.com - February 27 at 8:19 AM
Financial Survey: Regulus Therapeutics (RGLS) versus Pluristem Therapeutics (PSTI)Financial Survey: Regulus Therapeutics (RGLS) versus Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - February 27 at 5:14 AM
Pluristem Therapeutics (PSTI) Given a $3.00 Price Target at Maxim GroupPluristem Therapeutics (PSTI) Given a $3.00 Price Target at Maxim Group
www.americanbankingnews.com - February 25 at 1:50 PM
What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major InvestorsWhat You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors
finance.yahoo.com - February 16 at 8:18 AM
Pluristem Issues Letter to ShareholdersPluristem Issues Letter to Shareholders
finance.yahoo.com - February 7 at 9:41 AM
Pluristem Therapeutics (PSTI) Set to Announce Earnings on MondayPluristem Therapeutics (PSTI) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 5 at 4:00 AM
N.Korea threats spur U.S. search for new radiation therapiesN.Korea threats spur U.S. search for new radiation therapies
finance.yahoo.com - January 31 at 3:43 PM
Critical Comparison: GenVec (GNVC) and Pluristem Therapeutics (PSTI)Critical Comparison: GenVec (GNVC) and Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - January 11 at 5:36 AM
FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III StudyFDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study
finance.yahoo.com - January 9 at 10:13 AM
Pluristem Therapeutics (PSTI) versus ACADIA Pharmaceuticals (ACAD) Financial ContrastPluristem Therapeutics (PSTI) versus ACADIA Pharmaceuticals (ACAD) Financial Contrast
www.americanbankingnews.com - January 8 at 3:30 AM
 Brokerages Expect Pluristem Therapeutics Inc. (PSTI) to Post -$0.09 EPS Brokerages Expect Pluristem Therapeutics Inc. (PSTI) to Post -$0.09 EPS
www.americanbankingnews.com - January 5 at 11:06 PM
Does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Past Performance Indicate A Weaker Future?Does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Past Performance Indicate A Weaker Future?
finance.yahoo.com - December 25 at 6:08 PM
Pluristem Therapeutics (PSTI) Downgraded by ValuEnginePluristem Therapeutics (PSTI) Downgraded by ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
-$0.09 Earnings Per Share Expected for Pluristem Therapeutics, Inc. (PSTI) This Quarter-$0.09 Earnings Per Share Expected for Pluristem Therapeutics, Inc. (PSTI) This Quarter
www.americanbankingnews.com - December 20 at 1:18 PM
Pluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of "Buy" from AnalystsPluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 20 at 1:28 AM
Wired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem CellsWired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells
finance.yahoo.com - December 12 at 10:46 AM
Pluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head ComparisonPluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head Comparison
www.americanbankingnews.com - December 11 at 1:36 PM
Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual MeetingPluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
finance.yahoo.com - December 7 at 10:42 AM
Peer-Reviewed Article Published on Pluristems PLX-PAD Cells Mechanism of Action to Restore Blood Flow in ... - GlobeNewswire (press release)Peer-Reviewed Article Published on Pluristem's PLX-PAD Cells' Mechanism of Action to Restore Blood Flow in ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 4:34 PM
Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic TissuePeer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue
finance.yahoo.com - November 29 at 10:24 AM
Comparing Pluristem Therapeutics (PSTI) & The CompetitionComparing Pluristem Therapeutics (PSTI) & The Competition
www.americanbankingnews.com - November 25 at 5:10 PM
Pluristem Therapeutics (PSTI) Granted US Patent for Skeletal Muscle Regeneration - StreetInsider.comPluristem Therapeutics (PSTI) Granted US Patent for Skeletal Muscle Regeneration - StreetInsider.com
www.streetinsider.com - November 23 at 5:46 PM
Pluristem Therapeutics, Inc. (PSTI) Stock Rating Upgraded by Zacks Investment ResearchPluristem Therapeutics, Inc. (PSTI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 22 at 10:04 PM
Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial HighlightsPluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
finance.yahoo.com - November 15 at 7:40 AM
Pluristem Therapeutics, Inc. (PSTI) Announces  Earnings ResultsPluristem Therapeutics, Inc. (PSTI) Announces Earnings Results
www.americanbankingnews.com - November 14 at 7:16 AM
Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?
finance.yahoo.com - November 14 at 7:01 AM
Pluristem Therapeutics, Inc. (PSTI) Short Interest UpdatePluristem Therapeutics, Inc. (PSTI) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM
Pluristem reports 1Q lossPluristem reports 1Q loss
finance.yahoo.com - November 9 at 11:59 AM
Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHDPluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD
finance.yahoo.com - November 7 at 9:06 AM
Pluristem Therapeutics, Inc. (PSTI) to Release Earnings on MondayPluristem Therapeutics, Inc. (PSTI) to Release Earnings on Monday
www.americanbankingnews.com - November 6 at 6:54 AM
Pluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock ExchangePluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock Exchange
finance.yahoo.com - October 31 at 8:17 AM
Pluristem Therapeutics, Inc. (PSTI) Given Average Recommendation of "Hold" by BrokeragesPluristem Therapeutics, Inc. (PSTI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 31 at 1:34 AM
Pluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange AfterPluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After
www.nasdaq.com - October 30 at 6:15 AM

SEC Filings

Pluristem Therapeutics (NASDAQ:PSTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pluristem Therapeutics (NASDAQ:PSTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pluristem Therapeutics (NASDAQ PSTI) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.